Lcz696 an Innovation for Heart Failure
Heart failure (HF) is a crescent, solemn and multiple etiology worldwide health problem, which, besides potentially fatal, decreases the life quality of the affected people, mainly the elderly. Despite having obtained drugs that help in the disease development control, have been sought new alternatives for better management of these individuals. The LCZ696, a neprilysin inhibitor (sacubitril) associated with an ARB (valsartan) has shown signifiant improvements in patients' morbidity and mortality, which puts it as a good and interesting option for the treatment of heart failure.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access and Benefits of Publishing Open Access).